Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia
- PMID: 19362987
- DOI: 10.3816/CLM.2009.n.027
Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia
Abstract
Background: The aim of this study is to determine the serum immunoglobulin (Ig) M and serum viscosity (SV) levels at which retinal changes associated with hyperviscosity syndrome (HVS) as a result of Waldenström's macroglobulinemia (WM) occur. In addition, the effect of plasmapheresis on HVS-related retinopathy was tested.
Patients and methods: A total of 46 patients with WM received indirect ophthalmoscopy, laser Doppler retinal blood flow measurements, serum IgM, and SV determinations. A total of 9 patients with HVS were studied before and after plasmapheresis.
Results: Mean IgM and SV levels of patients with the earliest retinal changes were 5442 mg/dL and 3.1 cp, respectively. Plasmapheresis improved retinopathy, decreased serum IgM (46.5 +/- 18%; P = .0009), SV (44.7 +/- 17.3%; P = .002), retinal venous diameter (15.3 +/- 5.8%; P = .0001), and increased venous blood speed by +55.2 +/- 22.5% (P = .0004).
Conclusion: Examination of the retina is useful in identifying the symptomatic threshold of plasma viscosity levels in patients with HVS and can be used to gauge the effectiveness of plasmapheresis treatment.
Similar articles
-
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1157-60. doi: 10.1167/iovs.07-1254. Invest Ophthalmol Vis Sci. 2008. PMID: 18326744
-
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.Arch Ophthalmol. 2006 Nov;124(11):1601-6. doi: 10.1001/archopht.124.11.1601. Arch Ophthalmol. 2006. PMID: 17102008
-
Role of plasmapheresis in Waldenström's macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):238-40. doi: 10.1016/j.clml.2013.02.013. Epub 2013 Mar 20. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23522642 Review.
-
Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.Ther Apher Dial. 2024 Jun;28(3):417-423. doi: 10.1111/1744-9987.14094. Epub 2023 Dec 9. Ther Apher Dial. 2024. PMID: 38069574
-
Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):97-9. doi: 10.3816/CLM.2009.n.026. Clin Lymphoma Myeloma. 2009. PMID: 19362986 Review.
Cited by
-
Pathophysiology of Waldenström's macroglobulinemia.Haematologica. 2010 Mar;95(3):359-64. doi: 10.3324/haematol.2009.017251. Haematologica. 2010. PMID: 20207842 Free PMC article. No abstract available.
-
Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review.Ther Apher Dial. 2023 Feb;27(1):159-169. doi: 10.1111/1744-9987.13885. Epub 2022 May 28. Ther Apher Dial. 2023. PMID: 35583180 Free PMC article. Review.
-
How to manage Waldenstrom's macroglobulinemia.Leukemia. 2013 Apr;27(4):762-72. doi: 10.1038/leu.2013.36. Epub 2013 Feb 6. Leukemia. 2013. PMID: 23385376 Free PMC article. Review.
-
Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease.Case Rep Ophthalmol. 2013 Jul 26;4(2):64-9. doi: 10.1159/000354066. eCollection 2013. Case Rep Ophthalmol. 2013. PMID: 24019788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous